Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tocilizumab SC in Patients With Active Rheumatoid Arthritis and Inadequate Response to DMARDs. A Single-Arm, Open-Label Study to Evaluate Safety, Tolerability and Efficacy. In a Subgroup of Patients Inflammation Will Be Measured by Ultrasound

Next Previous
Search
Trial Profile

Tocilizumab SC in Patients With Active Rheumatoid Arthritis and Inadequate Response to DMARDs. A Single-Arm, Open-Label Study to Evaluate Safety, Tolerability and Efficacy. In a Subgroup of Patients Inflammation Will Be Measured by Ultrasound

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary) ; Corticosteroids
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms TOZULTRA; TOZURA
  • Sponsors Roche

Most Recent Events

  • 05 Jun 2021 Results (n=110) evaluating the associations between fatigue and inflammation by clinical, laboratory and ultrasound examinations during follow-up of rheumatoid arthritis patients on biological treatment, presented at the 22nd Annual Congress of the European League Against Rheumatism
  • 24 Oct 2018 Results (n=110) presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
  • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top